Tecan Group AG
SIX:TECN

Watchlist Manager
Tecan Group AG Logo
Tecan Group AG
SIX:TECN
Watchlist
Price: 203 CHF 2.78% Market Closed
Market Cap: 2.6B CHF
Have any thoughts about
Tecan Group AG?
Write Note

Tecan Group AG
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Tecan Group AG
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Tecan Group AG
SIX:TECN
Current Portion of Long-Term Debt
CHf11.5m
CAGR 3-Years
2%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Bachem Holding AG
SIX:BANB
Current Portion of Long-Term Debt
CHf146k
CAGR 3-Years
-90%
CAGR 5-Years
-69%
CAGR 10-Years
-42%
Siegfried Holding AG
SIX:SFZN
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Lonza Group AG
SIX:LONN
Current Portion of Long-Term Debt
CHf191m
CAGR 3-Years
-39%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
PolyPeptide Group AG
SIX:PPGN
Current Portion of Long-Term Debt
€46.9m
CAGR 3-Years
57%
CAGR 5-Years
49%
CAGR 10-Years
N/A
SKAN Group AG
SIX:SKAN
Current Portion of Long-Term Debt
CHf870k
CAGR 3-Years
-9%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
No Stocks Found

Tecan Group AG
Glance View

Market Cap
2.6B CHF
Industry
Life Sciences Tools & Services

Nestled in the heart of Switzerland lies Tecan Group AG, a company that has been quietly revolutionizing the laboratory world. Founded in 1980, Tecan has transformed itself from a small enterprise into a powerhouse in the life sciences and diagnostics sectors. The company's journey is one of precision and innovation, as it specializes in the development, production, and distribution of sophisticated laboratory instruments and solutions. These solutions are not merely products; they are the linchpins of automation that help streamline research, diagnostics, and the pharmaceutical sectors. Tecan's knack for integrating complex biochemical processes into accessible technology has proven critical for laboratories seeking speed and accuracy in processes like sample handling, testing, and data management. Tecan's business model thrives on a multifaceted approach. It sells its high-tech instruments and consumables directly to a diverse client base, including pharmaceutical companies, biotechnology firms, and research institutions. Beyond selling physical products, Tecan also benefits from providing value-added services such as after-sales support and bespoke system adaptations, ensuring that its clients can optimize their workflows. By combining cutting-edge technology with customer-centric service offerings, Tecan ensures recurring revenue streams. Its strategic prowess in securing long-term partnerships with leading institutions further cements its stance as not just a vendor, but a reliable partner in scientific discovery and healthcare advancement.

TECN Intrinsic Value
351.42 CHF
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Tecan Group AG's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
11.5m CHF

Based on the financial report for Jun 30, 2024, Tecan Group AG's Current Portion of Long-Term Debt amounts to 11.5m CHF.

What is Tecan Group AG's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
1%

Over the last year, the Current Portion of Long-Term Debt growth was -15%. The average annual Current Portion of Long-Term Debt growth rates for Tecan Group AG have been 2% over the past three years , 1% over the past five years .

Back to Top